⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
FXR/TGR5 Agonists
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-07-21 — β-Nicotinamide mononucleotide reduces aflatoxin B1 induced liver injury via the gut microbiota-bile acid-farnesoid X receptor (FXR/NR1H4) axis.: cross-connection with nad-precursors: NMN’s hepatoprotective effect in this mouse model runs through intestinal FXR/FGF15 activation, linking an NAD+ precursor to the bile acid–FXR signaling axis targeted directly by FXR/TGR5 agonists. (novelty: 3)